A positive readout for Medtronic's Tyrx envelope could mean an extra $1,000 per cardiac implant in the company's pocket.
Transcatheter mitral valve replacement is wrenching the spotlight away from the repair devices that grabbed the headlines last summer.
Despite encouraging interim pivotal data, Carmat’s artificial heart seems as far from market as ever.
The immensely complex and long-running intertwined litigation between the two medtechs has been brought to an end.
Mainstay Medical still hopes for US approval of its Reactiv8 device for chronic back pain despite trial failure.
The world’s first non-implanted vagus nerve stimulator is becoming established as a therapy for headache and migraine. But a move into autoimmune conditions will require…
The Swiss group has succeeded with its internally developed diagnostics, but buying in innovation has served Becton Dickinson well.
Abbott Laboratories has posted decent results for its transcatheter aortic valve, but all-important US pivotal data are in the offing.
The industry leader’s biggest buy since Covidien gets it into robots, but direct competition with Intuitive is unlikely.